Premium
Treatment‐induced stable, moderate reduction in blood cell counts correlate to disease control in early rheumatoid arthritis
Author(s) -
Lester S. E.,
Proudman S. M.,
Lee A. T. Y.,
Hall C. A.,
McWilliams L.,
James M. J.,
Cleland L. G.
Publication year - 2009
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/j.1445-5994.2008.01737.x
Subject(s) - medicine , rheumatoid arthritis , methotrexate , disease , adverse effect , lymphocyte , platelet , toxicity , arthritis , immunology , monocyte
Background: Treatment of rheumatoid arthritis (RA) has become more intensive, thereby raising concerns regarding toxicities, including leucopenia. The objective was to analyse cell counts obtained as routine surveillance for adverse effects to assess the effect of intensive treatment and treatment dosage and to examine correlations to disease activity scores. Methods: Patients with early RA were treated with combinations of disease‐modifying anti‐inflammatory drugs according to pre‐defined rules, with dose adjustments contingent on residual disease activity and tolerance. Results: Mean leucocyte, neutrophil and platelet counts fell with levels that correlated to disease activity scores. The strongest correlation was between platelets and disease activity scores. There was a modest, inverse correlation between methotrexate dose and monocyte and lymphocyte counts. No serious toxicity associated with the therapy was seen. Conclusion: Moderate reductions in cell counts are well tolerated in RA and appear to contribute to disease control.